Full Press Release Details
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer.
IDYA
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
Key Takeaway: IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
Price reaction · baseline $31.63 (2023-12-01 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma